Novavax Inc. Vaccine Update
- By BSTQ Staff
Novavax Inc. announced positive preclinical data for its virus-like particle (VLP) vaccine candidate against A(H7N9) influenza. The study examined the immunogenicity and efficacy of two doses of its A(H7N9) VLP vaccine candidate against a lethal wild-type challenge mouse model. Three control groups included Novavax’ non-homologous A(H7N3) VLP vaccine candidate, its A(H5N1) VLP vaccine candidate and a placebo. All vaccine candidates were administered with or without Iscomatrix, a saponin-based adjuvant. The data were published online in the peer-reviewed journal Vaccine.
